Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma

Published 2015 View Full Article

Authors

Keywords

EGFR mutation, EGFR-TKI therapy, Immunohistochemistry, Lung adenocarcinoma, PD-L1

Journal

Clinical Lung Cancer

Volume 16, Issue 5, Pages e25-e35

Publisher

Elsevier BV

Online

2015-02-19

DOI

10.1016/j.cllc.2015.02.002

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started